Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UCB Major Shareholding Notification 2024

Oct 1, 2024

4017_mrq_2024-10-01_2903928b-ace7-420d-8d90-87da7464c53a.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

Transparency notification BlackRock, Inc.

Brussels (Belgium), 1 st October 2024 – 20:00 (CEST)Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), dated 26 September 2024.

BlackRock, Inc. notified that, following an acquisition of UCB shares with voting rights or assimilated financial instruments by its affiliates, its shareholding in UCB SA increased and crossed the 5% threshold on 25 September 2024.

On 25 September 2024, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 803 556 UCB shares with voting rights or assimilated financial instruments, representing 5.04% of the total number of shares issued by the company (194 505 658), versus 4.98% (9 686 622 UCB shares or assimilated financial instruments) in the previous notification dated 25 September 2024.

2. Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights, acquisition or disposal of financial instruments that are treated as voting securities.
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement:

Name Address (for legal entities)
BlackRock, Inc. 50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock (Netherlands) B.V. Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited 20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited 12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC 50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Asset Management Canada Limited 161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada
BlackRock Asset Management Deutschland AG Lenbachplatz 1 1st Floor, Munich, 80333-MN3, Germany
BlackRock Asset Management North Asia Limited 15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong
Kong
BlackRock Financial Management, Inc. 50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Fund Advisors 400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National
Association
400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Investment Management (Australia) Limited Level 37 Chifley Tower, 2 Chifley Square, Sydney NSW 2000, Australia
BlackRock Investment Management (UK) Limited 12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC 1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd. 1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan
Aperio Group, LLC 3 Harbor Dr Suite 204, Sausalito, CA 94965, U.S.A.
SpiderRock Advisors, LLC Corporation Service Company, 251 Little Falls Drive, Wilmington, DE 19808, U.S.A.
  • Date on which the threshold is crossed: 25 September 2024.
  • Threshold crossed (in %): 5%.
  • Denominator: 194 505 658.
  • Notified details:

UCB News

A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities
Linked to securities Not linked to the
securities
BlackRock, Inc. 0 0 0,00%
BlackRock (Netherlands) B.V. 3.219 3.219 0,00%
BlackRock (Singapore) Limited 5.055 5.055 0,00%
BlackRock Advisors (UK) Limited 1.584.289 1.701.382 0,87%
BlackRock Advisors, LLC 87.072 87.072 0,04%
BlackRock Asset Management Canada
Limited
131.297 131.194 0,07%
BlackRock Asset Management
Deutschland AG
178.545 178.545 0,09%
BlackRock Asset Management North
Asia Limited
3.524 3.524 0,00%
BlackRock Financial Management, Inc. 72.623 69.611 0,04%
BlackRock Fund Advisors 2.528.256 2.526.855 1,30%
BlackRock Institutional Trust Company,
National Association
1.618.585 1.619.573 0,83%
BlackRock Investment Management
(Australia) Limited
52.088 52.088 0,03%
BlackRock Investment Management
(UK) Limited
2.572.439 2.570.940 1,32%
BlackRock Investment Management,
LLC
562.667 562.668 0,29%
BlackRock Japan Co., Ltd. 234.208 234.207 0,12%
Aperio Group, LLC 39.982 39.982 0,02%
Subtotal 9.673.850 9.785.915 5,03%
TOTAL 9.785.915 0 5,03% 0,00%
B) Equivalent financial instruments After the transaction
Holders of equivalent
financial instruments
Type of financial instrument Expiration date Exercise period or
date
# of voting rights
that may be
acquired if the
instrument is
exercised
% of voting rights Settlement
BlackRock Advisors (UK) Limited Securities Lent 3.670 0.00% physical
BlackRock Investment Management
(UK) Limited
Securities Lent 596 0,00% physical
BlackRock Advisors, LLC Contract for Difference 6.745 0,00% cash
BlackRock Financial Management, Inc. Contract for Difference 506 0,00% cash
BlackRock Institutional Trust Company,
National Association
Contract for Difference 1.399 0,00% cash
Aperio Group, LLC Depositary Receipt 4.704 0.00%
SpiderRock Advisors, LLC Depositary Receipt 21 0.00%
TOTAL 17.641 0,01%

TOTAL (A & B) # of voting rights % of voting rights
CALCULATE 9.803.556 5,04%

Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in the 'Chain of Control' tab.

Additional information: The disclosure obligation arose due to total holdings in voting rights for BlackRock, Inc. going above 5%. Additionally, voting rights attached to shares for BlackRock, Inc. went above 5%.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.

For further information, contact UCB:

Investor Relations Antje Witte T +32 2 559 94 14 [email protected]

Corporate Communications Laurent Schots T+32 2 559 92 64 [email protected]

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news